Calculating the Regulatory Review Period for Patent Term Extension: A Comprehensive Guide
Understanding the intricacies of patent term extension (PTE) is crucial for innovators and businesses alike. One of the most critical […]
Guest Content
Social Return on Investment
This is a guest post by Oleksandr Topachevskyi at Digital Health Outcomes. Oleksandr may be contacted at sales@digitalho.com Commercial, nonprofit,
The value of method of use patent claims in protecting your therapeutic assets
This is a guest post by Ray Miller and Megan E. Bowers, Ph.D. at DLA Piper. Ray may be contacted
The value of method of use patent claims in protecting your therapeutic assets Read Post »
Bayer’s in silico ADMET platform: a journey of machine learning over the past two decades
This paper was originally published by Andreas H. Göller, Lara Kuhnke, Floriane Montanari, Anne Bonin, Sebastian Schneckener, Antoniuster Laak, Jörg
Development of Generic Drug Products by Pharmaceutical Industries Considering Regulatory Aspects: A Review
This paper was originally published by Md. Imtiaz Hasan et al in Journal of Biosciences and Medicines under a Creative Commons
Indian Pharma—Some Challenges and Acceptances
Introduction The Indian pharmaceutical industry has been a significant player in the global market for decades. Known for its generic
Getting the most out of pharmaceutical patent-term extensions in Russia
This is a guest post by Shamil Gizatullin, Gowling WLG (International) Inc. shamil.gizatullin@gowlingwlg.com Although it has become harder to obtain
Getting the most out of pharmaceutical patent-term extensions in Russia Read Post »
Business Continuity and Resiliency Planning for Biomedical and Research Organizations
By Nanette Moss, S.M., C.I.H., Senior Scientist and Project Executive with Environmental Health & Engineering, Inc. What is business continuity
Business Continuity and Resiliency Planning for Biomedical and Research Organizations Read Post »
Obviousness-Type Double Patenting Just Became Less of a Problem for Innovators
This is a guest post from Pepper Hamilton Partners John P. Isacson and N. Nicole Stakleff. John can be contacted
Obviousness-Type Double Patenting Just Became Less of a Problem for Innovators Read Post »
